Monday, 23 September 2019

Vanda Pharma withdraws application for Fanaptum

15 March 2013 | Regulatory | By BioSpectrum Bureau

The company withdrew application after the CHMP identified missing data

The company withdrew application after the CHMP identified missing data

Singapore: Vanda Pharmaceuticals has withdrawn its application from European Medicines Agency for a centralized marketing authorization for the medicine Fanaptum (iloperidone) intended to be used for the treatment of schizophrenia.

The application for the marketing authorisation for Fanaptum was submitted to the Agency on June 27, 2011. On December 13, 2012, the Committee for Medicinal Products for Human Use (CHMP) recommended the refusal of a marketing authorisation for the medicinal product. The company has requested a re-examination of the opinion in February 2013. At the time of the withdrawal, the medicine was under review by the CHMP.

In its official letter, the company stated that it is withdrawing the application because the CHMP identified missing data which will not be available in a timeframe acceptable in the centralised procedure.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Is Pharma innovation getting inhibited in APAC?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls